VRTX Q4 2019 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$125B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.4B+62.4% YoY

Gross Profit

$1.2B86.9% margin

Operating Income

$551M39.0% margin

Net Income

$583M41.3% margin

EPS (Diluted)

$2.23

QoQ Revenue Growth

+48.8%

Cash Flow

Operating Cash Flow

$446M

Free Cash Flow

$429M

Stock-Based Comp.

$92M

Balance Sheet

Total Assets

$8.3B

Total Liabilities

$2.2B

Stockholders' Equity

$6.1B

Cash & Equivalents

$3.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.4B	$870M	+62.4%
Gross Profit	$1.2B	$748M	+64.2%
Operating Income	$551M	$128M	+331.8%
Net Income	$583M	$1.6B	-62.4%

Revenue Segments

ORKAMBI

$426M30%

TRIKAFTA/KAFTRIO

$420M30%

SYMDEKO/SYMKEVI

$332M23%

KALYDECO

$236M17%

Geographic Segments

UNITED STATES

$1.0B51%

Non-US

$617M31%

Europe

$353M18%